SLC5A2 and type 2 diabetes mellitus: Recent studies showing that drugs that inhibit the sodium–glucose co-transport at proximal tubular levels (sodium–glucose co-transporter 2 [SGLT2] inhibitors) may offer substantial nephro- and cardioprotection to patients with type 2 diabetes and different levels of albuminuria [29,30] might pave the way to novel prevention strategies based on the integrated use of these novel medications with an ACE inhibitor or an ARB, but not with their combination.